Charles River, Distributed Bio enter partnership for antibody discovery platform
Charles River Laboratories International announced that it has entered into an exclusive partnership with Distributed Bio. This partnership will grant Charles River's clients access to Distributed Bio's antibody libraries and integrated antibody optimization technologies. Distributed Bio's libraries are computationally optimized for both sequence diversity and engineering fitness through the analysis of thousands of human antibody repertoires and all known monoclonal therapeutics in clinical trials. A combination of Distributed Bio's antibody libraries and Charles River's extensive drug development expertise will create a unique end-to-end platform for therapeutic antibody discovery and development. With a focus on speed and design, this partnership will help increase the probability of success for delivering high-quality antibody candidates.